Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011408
Filing Date
2025-08-13
Accepted
2025-08-13 17:11:06
Documents
61
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20250630x10q.htm   iXBRL 10-Q 2181112
2 EX-31.1 tbph-20250630xex31d1.htm EX-31.1 13339
3 EX-31.2 tbph-20250630xex31d2.htm EX-31.2 14142
4 EX-32 tbph-20250630xex32.htm EX-32 16126
  Complete submission text file 0001558370-25-011408.txt   7723323

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20250630.xsd EX-101.SCH 45193
6 EX-101.CAL tbph-20250630_cal.xml EX-101.CAL 51419
7 EX-101.DEF tbph-20250630_def.xml EX-101.DEF 160814
8 EX-101.LAB tbph-20250630_lab.xml EX-101.LAB 388387
9 EX-101.PRE tbph-20250630_pre.xml EX-101.PRE 270779
64 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20250630x10q_htm.xml XML 1435829
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)